within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA11_PravastatinAndEzetimibe;
model PravastatinAndEzetimibe 
   extends Pharmacolibrary.Drugs.ATC.C.C10BA11;

  annotation(Documentation(
    info ="<html><body><p>Pravastatin and ezetimibe is a fixed-dose combination medication used for the treatment of hypercholesterolemia and mixed dyslipidemia. Pravastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, while ezetimibe is a cholesterol absorption inhibitor that decreases cholesterol uptake in the intestine. This combination is approved and widely used when treatment with diet and a single agent is inadequate.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic models combining pravastatin and ezetimibe as a fixed-dose combination have been reported in the published literature. Therefore, the following parameters represent an estimated profile based on data from individual components in healthy adult subjects.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Garner, RM, et al., &amp; Jorkasky, DK (2019). Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects. <i>Clinical and translational science</i> 12(6) 667–676. DOI:<a href=&quot;https://doi.org/10.1111/cts.12672&quot;>10.1111/cts.12672</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31343124/&quot;>https://pubmed.ncbi.nlm.nih.gov/31343124</a></p></li><li><p>Kawase, A, et al., &amp; Iwaki, M (2015). Pravastatin Modulate Niemann-Pick C1-Like 1 and ATP-Binding Cassette G5 and G8 to Influence Intestinal Cholesterol Absorption. <i>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</i> 18(5) 765–772. DOI:<a href=&quot;https://doi.org/10.18433/j3m029&quot;>10.18433/j3m029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26670369/&quot;>https://pubmed.ncbi.nlm.nih.gov/26670369</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end PravastatinAndEzetimibe;
